 |
인쇄하기
취소
|
Rheumatoid arthritis market to get heated
Competition is about to heat up in the domestic rheumatoid arthritis market as Green Cross Corp. will also join the market by launching its newly developed natural drug “Shinbaro” from next month.
A 12-week study over Pfizer’s Cerebrex indicated that Shinbaro is not inferior to the control drug with less adverse drug reactions, according to the company. The preclinical test results also show...
A 12-week study over Pfizer’s Cerebrex indicated that Shinbaro is not inferior to the control drug with less adverse drug reactions, according to the company. The preclinical test results also show...
Fees
- Email service daily and homepage access.
- $300 per month.
- 5 Email holders per each company.
- Anual contract base.
Copyright Yakup.com All rights reserved.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.